Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xepa-soul pattinson (malaysia) sdn bhd - chloramphenicol -

Kenya - English - Pharmacy and Poisons Board

xepa-soul pattinson(m)sdn bhd 1-5 cheng industrial estate 75250 melaka malaysia - chloramphenicol - eye drops - chloramphenicol 0.5% w/v - ophthalmological anti-infectives: antibiotics

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xepa-soul pattinson (malaysia) sdn bhd - chlorpheniramine maleate; paracetamol; phenylephrine hydrochloride -

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)] . when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and main

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and main

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and main

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 17), efficacy was established in one 6-week trial [see clinical studies ( 14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and main

Australia - English - Department of Health (Therapeutic Goods Administration)

herbal world pty ltd - turnera diffusa, quantity: 37.5 microgram/ml (equivalent: turnera diffusa, qty 150 microgram/ml; equivalent: beta-arbutin, qty 1.05 microgram/ml); oenothera biennis, quantity: 25 microgram/ml (equivalent: oenothera biennis, qty 100 microgram/ml); dioscorea villosa, quantity: 625 microgram/ml (equivalent: dioscorea villosa, qty 2.5 mg/ml); malpighia glabra, quantity: 82.5 microgram/ml (equivalent: malpighia glabra, qty 825 microgram/ml; equivalent: ascorbic acid, qty 10 microgram/ml); matricaria chamomilla, quantity: 125 microgram/ml (equivalent: matricaria chamomilla, qty 500 microgram/ml) - oral liquid - excipient ingredients: potable water; sodium benzoate; carbon dioxide; sucrose; maltodextrin; citric acid; vanillin; linalool; delta-decalactone; neryl acetate; ethyl propionate; ethyl butyrate; citronellal; anethole; methyl benzoate; buchu leaf oil; dimethyl anthranilate; propylene glycol; phenethyl alcohol; mandarin oil; benzyl acetate; ethyl acetate; ethanol; orange oil; phenylacetaldehyde; cis-3-hexen-1-ol; geraniol; trans-2-hexenol; terpinen-4-ol; limonene; citral; maltol; menthone; ethyl caprate; petitgrain oil; isoamyl acetate; davana oil; rose oil; linalyl acetate; geranyl acetate; bergamot oil; benzaldehyde; l-menthyl acetate; orange flower oil; ethyl enantate; benzyl alcohol; alpha-phellandrene; isovaleric acid; geranyl butyrate; lemon oil terpeneless; cinnamon leaf oil; piperonal; gamma-decalactone; jasmine absolute; ginger oil; terpineol; hexyl acetate; acetic acid; 4-(para-hydroxyphenyl)-2-butanone; decanal; alpha-irone; alpha-terpineol; benzyl benzoate; caprylic aldehyde; butylated hydroxytoluene; nerol; sweet orange oil terpenes and terpenoids; geranyl propionate; gamma-heptalactone; linalyl isobutyrate; ethyl salicylate; 2,6-nonadien-1-ol; dwarf pine-needle oil; ambrette seed oil; methyl anthranilate; dimethyl sulfide; lauryl aldehyde; terpinyl acetate - helps reduce/decrease free radical damage to body cells ; maintain/support cardiovascular system health ; decrease/reduce/relieve diarrhoea ; help maintain/support emotional wellbeing ; decrease/reduce/relieve symptoms of common cold ; decrease/reduce/relieve cough ; decrease/reduce/relieve throat irritation

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - methotrexate - oral tablet - 10mg